文献速递核素与放射性配体治疗放射性药物与辐射防护

治疗前可溶性肿瘤坏死因子受体1与肝细胞生长因子预测钇-90放射栓塞后毒性与总生存

Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity.
PubMed 文献 · J Nucl Med · 2021-09-09

该研究分析43例接受钇-90放射栓塞治疗肝内恶性肿瘤患者的治疗前血细胞因子水平,发现可溶性肿瘤坏死因子受体1(sTNFR1)和肝细胞生长因子(HGF)与肝毒性及总生存相关,且在校正剂量参数后仍为独立预测因子。结论提示细胞因子可用于个体化预测放射栓塞结局。

要点

  • 治疗前sTNFR1(P=0.045)和HGF(P=0.005)水平与放射栓塞后肝毒性相关。
  • sTNFR1(HR 12.3,95%CI 3.5-42.5,P<0.001)和HGF(HR 7.5,95%CI 2.4-23.1,P<0.001)预测总生存。
  • 剂量参数和基线肝功能与肝毒性无关,细胞因子是唯一预测因素。

核心结论

  • 治疗前血细胞因子sTNFR1和HGF水平可预测钇-90放射栓塞后的肝毒性和总生存。

研究设计与样本

  • 前瞻性方案中43例接受钇-90放射栓塞治疗肝内原发(48.8%[21/43])或继发(51.2%[22/43])恶性肿瘤的患者。
  • 治疗前血样用酶联免疫吸附法检测sTNFR1和HGF,治疗后钇-90 PET/CT导出剂量参数。
  • 毒性定义为白蛋白-胆红素评分从基线至随访(治疗后3-6个月)的变化。

主要发现

  • 单变量模型中sTNFR1(P=0.045)和HGF(P=0.005)与肝毒性相关。
  • 多变量模型(含剂量参数和既往肝脏定向治疗)中细胞因子是唯一毒性预测因素。
  • sTNFR1(HR 12.3,95%CI 3.5-42.5,P<0.001)和HGF(HR 7.5,95%CI 2.4-23.1,P<0.001)预测总生存。
  • 控制吸收剂量和转移性疾病后生存预测结果相似。
  • 所检测的剂量参数和基线肝功能与肝毒性无关。

关键数值与推荐

  • 肝毒性定义为白蛋白-胆红素评分从基线至治疗后3-6个月随访的变化。
  • sTNFR1单变量肝毒性P=0.045,HGF单变量肝毒性P=0.005。
  • sTNFR1总生存HR 12.3(95%CI 3.5-42.5,P<0.001),HGF总生存HR 7.5(95%CI 2.4-23.1,P<0.001)。

临床怎么用

  • 治疗前可检测sTNFR1和HGF以辅助预测钇-90放射栓塞后肝毒性和生存风险。
  • 针对TNFα轴的干预可考虑用于未来预防肝毒性的研究。
  • HGF需进一步研究以明确其升高是驱动毒性还是提示既往损伤后的肝脏再生。

局限性

  • 样本量43例,结论需更大样本验证。
  • 细胞因子仅选sTNFR1和HGF两项,基于既往立体定向体部放疗研究。
  • 毒性定义采用白蛋白-胆红素评分变化,随访时间为治疗后3-6个月。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Liver function may be negatively affected by radiation for treatment of hepatic malignancy. Pretreatment blood cytokine levels are biomarkers for prediction of toxicity and survival after external-beam radiation therapy. We hypothesized that cytokines may also predict outcomes after radioembolization, enabling a biomarker-driven personalized approach to treatment. Methods: Pretherapy blood samples from patients enrolled on a prospective protocol evaluating 90Y radioembolization for management of intrahepatic malignancy were analyzed for 2 cytokines selected on the basis of prior studies in stereotactic body radiotherapy, soluble tumor necrosis factor receptor 1 (sTNFR1) and hepatocyte growth factor (HGF), via enzyme-linked immunosorbent assay, and key dosimetric parameters were derived from posttreatment 90Y PET/CT imaging. Toxicity was defined as a change in albumin-bilirubin score from baseline to follow-up (3-6 mo after treatment). Associations of cytokine levels, dose metrics, and baseline liver function with toxicity and overall survival were assessed. Results: Data from 43 patients treated with 90Y radioembolization for primary (48.8% [21/43]) or secondary (51.2% [22/43]) malignancy were assessed. Examined dose metrics and baseline liver function were not associated with liver toxicity; however, levels of sTNFR1 (P = 0.045) and HGF (P = 0.005) were associated with liver toxicity in univariate models. Cytokines were the only predictors of toxicity in multivariable models including dose metrics and prior liver-directed therapy. sTNFR1 (hazard ratio, 12.3; 95% CI, 3.5-42.5, P < 0.001) and HGF (hazard ratio, 7.5; 95% CI, 2.4-23.1, P < 0.001) predicted overall survival, and findings were similar when models were controlled for absorbed dose and presence of metastatic disease. Conclusion: Pretreatment cytokine levels predict liver toxicity and overall survival. These pathways can be targeted with available drugs, an advantage over previously studied dose metrics and liver function tests. Interventions directed at the TNFα-axis should be considered in future studies for prevention of liver toxicity, and HGF should be explored further to determine whether its elevation drives toxicity or indicates ongoing liver regeneration after prior injury.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Cousins MM, Devasia TP, Maurino CM, et al. Pretreatment Levels of Soluble Tumor Necrosis Factor Receptor 1 and Hepatocyte Growth Factor Predict Toxicity and Overall Survival After 90Y Radioembolization: Potential Novel Application of Biomarkers for Personalized Management of Hepatotoxicity. J Nucl Med. 2021. PMID: 34503962. doi:10.2967/jnumed.121.262447

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。